DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
44 hedge funds and large institutions have $16.5M invested in DMK Pharmaceuticals Corporation Common Stock in 2017 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 4 closing their positions.
350% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 4
216% more call options, than puts
Call options by funds: $5.14M | Put options by funds: $1.62M
180% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 5
47% more funds holding
Funds holding: 30 → 44 (+14)
2.76% less ownership
Funds ownership: 14.3% → 11.54% (-2.8%)
13% less capital inflows, than outflows
Capital inflows: $5.91M | Capital outflows: $6.79M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Perceptive Advisors
New York
|
+$1.71M |
| 2 |
EAM Investors
Solana Beach,
California
|
+$1M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$732K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$412K |
| 5 |
BlackRock
New York
|
+$319K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sio Capital Management
New York
|
-$3.25M |
| 2 |
Axiom Investors
Greenwich,
Connecticut
|
-$1.7M |
| 3 |
Pura Vida Investments
New York
|
-$956K |
| 4 |
Raymond James & Associates
St Petersburg,
Florida
|
-$732K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$74.9K |
DMK Hedge Fund Activity: Q2 2017 in Review
44 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q2 2017, worth a combined $16.5M — up 15% from $14.4M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new DMK positions and 4 closed out — a net gain of 14 holders — while 14 added to existing stakes and 5 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $1.71M. The largest seller was Sio Capital Management, cutting an estimated $3.25M.
- 44 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q2 2017, up from 30 in Q1 2017.
- Funds reported $16.5M of DMK Pharmaceuticals Corporation Common Stock stock for Q2 2017, up 15% quarter-over-quarter.
- 18 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q2 2017 and 4 closed out, a net change of +14 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q2 2017 was Perceptive Advisors, an estimated $1.71M added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q2 2017 was Sio Capital Management, an estimated $3.25M sold.
Based on aggregated 13F filings for Q2 2017.